Levetiracetam Mechanisms of Action: From Molecules to Systems
Open accessThe DOI matches its Crossref record; 302 of the 303 references it cites were found in a registry or an index.
Abstract
Epilepsy is a chronic disease that affects millions of people worldwide. Antiepileptic drugs (AEDs) are used to control seizures. Even though parts of their mechanisms of action are known, there are still components that need to be studied. Therefore, the search for novel drugs, new molecular targets, and a better understanding of the mechanisms of action of existing drugs is still crucial. Levetiracetam (LEV) is an AED that has been shown to be effective in seizure control and is well-tolerable, with a novel mechanism of action through an interaction with the synaptic vesicle protein 2A (SV2A). Moreover, LEV has other molecular targets that involve calcium homeostasis, the GABAergic system, and AMPA receptors among others, that might be integrated into a single mechanism of action that could explain the antiepileptogenic, anti-inflammatory, neuroprotective, and antioxidant properties of LEV. This puts it as a possible multitarget drug with clinical applications other than for epilepsy. According to the above, the objective of this work was to carry out a comprehensive and integrative review of LEV in relation to its clinical uses, structural properties, therapeutical targets, and different molecular, genetic, and systemic action mechanisms in order to consider LEV as a candidate for drug repurposing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across models of stress, epilepsy, and neurodegeneration, modulation of SV2A preserves synaptic structure and maintains transmission after plasticity induction [173,175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Functionally, SV2A modulation limits the slide from induced plasticity to maladaptive remodeling and relapse-like behavior [175,199,205].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“After ketamine or other plasticity-promoting interventions, preserving vesicle cycling and maintaining a competent readily releasable pool appear crucial for sustaining gains; animal studies link antidepressant durability to synaptic integrity supported by SV2A pathways and complementary signaling through ERK and calcium channels [199,201,205].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Levetiracetam restores vesicle fusion fidelity, rescues basal transmission, and normalizes synaptic protein composition, effects that depend on direct SV2A engagement and extend to hippocampal volume and plasticity recovery [173,175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In stress-sensitized and developmental perturbation paradigms, levetiracetam reverses anxiety-like, cognitive, and social deficits while rebalancing hippocampal and mesolimbic activity, consistent with network-level stabilization of prefrontal–hippocampal circuits [175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ILAE official report: a practical clinical definition of epilepsy
Fisher, R. S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J. H., Elger, C. E., Engel, J., Forsgren, L., French, J. A., Glynn, M., et al. (2014) · Epilepsia · doi:10.1111/epi.12550 · Cited by 6,108 · cited 1×
“It is a chronic neurological disorder characterized by the presence of spontaneous and recurrent seizures caused by hyperactivity and the abnormal synchronization of neurons [2] that results in neuronal damage, inflammation, and the generation of reactive oxygen species”
BackgroundFisher, R. S., Cross, J. H., French, J. A., Higurashi, N., Hirsch, E., Jansen, F. E., Lagae, L., Moshé, S. L., Peltola, J., Roulet Perez, E., et al. (2017) · Epilepsia · doi:10.1111/epi.13670 · Cited by 3,483 · cited 1×
“According to the International League Against Epilepsy (ILAE), epileptic seizures are classified as focal-onset, generalized-onset, and unknown-onset seizures (previously known as partial and generalized seizures) [3].”
BackgroundTrinka, E., Cock, H., Hesdorffer, D., Rossetti, A. O., Scheffer, I. E., Shinnar, S., Shorvon, S., & Lowenstein, D. H. (2015) · Epilepsia · doi:10.1111/epi.13121 · Cited by 2,494 · cited 1×
“Status epilepticus (SE) is an emergency condition characterized by long-term seizures in which seizures lasting more than 30 min can be fatal [43]; benzodiazepines have been used as a first-line treatment for this condition.”
BackgroundThe role of inflammation in epilepsy
Vezzani, A., French, J., Bartfai, T., & Baram, T. Z. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.178 · Cited by 1,876
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 2×
“Currently, there is no doubt that LEV binds in a saturable, reversible, and stereospecific manner to SV2A in both rat and human brains; this is also true for its structural analogs [9,103].”
BackgroundGlia and epilepsy: excitability and inflammation
Devinsky, O., Vezzani, A., Najjar, S., De Lanerolle, N. C., & Rogawski, M. A. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.008 · Cited by 867
Buckley, K., & Kelly, R. B. (1985) · The Journal of cell biology · doi:10.1083/jcb.100.4.1284 · Cited by 712
Pitkänen, A., & Sutula, T. P. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00073-x · Cited by 637 · cited 1×
“Antiepileptic drugs (AEDs; also named antiseizure drugs) efficiently control seizures, but only in about 2/3 of people with epilepsy [4]; moreover, during the last few years it has become clear that the current way of treating epilepsy with AEDs that only controls seizures is insufficient, since it does not cover the…”
BackgroundLevetiracetam for partial seizures: Results of a double-blind, randomized clinical trial
Cereghino, J. J., Biton, V., Abou-Khalil, B., Dreifuss, F., Gauer, L. J., Leppik, I., & the United States Levetiracetam Study Group (2000) · Neurology · doi:10.1212/wnl.55.2.236 · Cited by 524
Pharmacokinetic profile of levetiracetam
Patsalos, P. N. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00052-2 · Cited by 519
Research works printed but not linked: 1
- Bonifacio S.L. Gonzalez F. Ferriero D.M. Chapter 61—Central Nervous System Injury and Neuroprotection Avery’s Diseases of the Newborn (Ninth Edition) Christine A.G. Devaskar S.U. W.B. Saunders Philadelpia, PA, USA 2012 869 891 978-1-4377-0134-0
Cited by
Items 101–146 of 146
eLife Assessment: On-Demand Seizures Facilitate Rapid Screening of Therapeutics for Epilepsy
Scharfman, H. E. (2024) · eLife · doi:10.7554/elife.101859.1.sa4
On-Demand Seizures Facilitate Rapid Screening of Therapeutics for EpilepsyPreprint
Chen, Y., Litt, B., Vitale, F., & Takano, H. (2024) · eLife · doi:10.7554/elife.101859.1
On-demand seizures facilitate rapid screening of therapeutics for epilepsyPreprint
Chen, Y., Litt, B., Vitale, F., & Takano, H. (2024) · eLife · doi:10.7554/elife.101859
“Diazepam, a benzodiazepine that interacts with GABA receptors, is commonly prescribed for first line control of convulsive seizures (42) , whereas levetiracetam is an anticonvulsant that reduces overall network excitability through effects mediated by the synaptic protein SV2A (43) .”
A Review on Molecular Mechanism of Antiepileptic Drugs
-, T. C. S. (2024) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2024.v06i06.33763
Status Epilepticus and Refractory Status Epilepticus
Trammel, M., Sasannejad, C., Tomita, B., & Chang, C. W. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-77335-8_18
Erdeve, E. T., Onat, F., & Çarçak, N. (2025) · Archives of Epilepsy · doi:10.4274/archepilepsy.2025.25135
On-Demand Seizures Facilitate Rapid Screening of Therapeutics for EpilepsyPreprint
Chen, Y., Litt, B., Vitale, F., & Takano, H. (2025) · eLife · doi:10.7554/elife.101859.2
Samudra, E., Ketaren, R. J., & Inggas, M. A. M. (2025) · Magna Neurologica · doi:10.20961/magnaneurologica.v3i2.1882
Zamani, I., Khan, M., Manzardo, A. M., & Khanzada, N. (2025) · Cureus · doi:10.7759/cureus.87919
Effects of tramadol and levetiracetam in preventing peridural fibrosis after laminectomy in rats
Bulut, İ. U., Yüksel, U., Kartal, B., Ceylan‐Isik, A. F., Karagedik, M. İ., Özdemir, A., Öğden, M., & Bakar, B. (2025) · Neurological Research · doi:10.1080/01616412.2025.2538130
“Levetiracetam, which has anti-epileptic activity, also exhibits anti-hyperalgesic, anti-inflammatory, antioxidant, and antiapoptotic properties [16].”
Movahedinia, M., Mirjalili, S. R., Ardekani, N. A., & Shamsi, F. (2025) · eNeurologicalSci · doi:10.1016/j.ensci.2025.100583
“[10] While intravenous levetiracetam is widely used in older children and adults, its application in neonates remains under investigation.”
Hüsunet, M. T., & Bılgın, B. (2025) · Meandros Medical And Dental Journal · doi:10.69601/meandrosmdj.1623741
Jakubiec, M., Abram, M., Zagaja, M. P., Socała, K., Panic, V., Latacz, G., Mogilski, S., Szafarz, M., Szewczyk, A., Saunders, J., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118728
Case Series Assessing the Use of Levetiracetam for Gait Improvement in Primary Lateral Sclerosis
Allen, M. D., Carter, D., Warman‐Chardon, J., Zwicker, J. C., & Breiner, A. (2025) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2025.10465
“7 – 9 A centrally mediated mechanism of action is postulated based on both levetiracetam ’ s pharmacology and the clinical symptoms it has been shown to benefit, aside from seizure disorders.”
Yang, T., Chen, C., Ma, L., & Zhou, Y. C. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178427
Farmacovigilancia activa en el escenario clínico
Oricchio, F. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Seizure control after surgical resection of low-grade Gliomas: A Regional retrospective analysis
Bakhshi, S. K., Tariq, R., Urooj, F., Masood, S., Mirza, F. A., & Enam, S. A. (2025) · World Neurosurgery X · doi:10.1016/j.wnsx.2025.100548
Miller, C. O. G. (2025) · Springer eBooks · doi:10.1007/978-3-032-13315-1_2
Kebriaeezadeh, A., Zaferi, R., Sharifzadeh, M., Mirnajafi-zadeh, J., Taghizadeh, G., Gheibi, H., & Rezaei, M. (2026) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-025-00583-w
“Mechanistically, levetiracetam specifically binds to and inhibits the transmembrane protein located on the synaptic vesicle SV2A, thereby hindering the neurotransmitter priming and intensification of neurotransmission during exaggerated provocation of presynaptic fibers [ 23 ].”
Tieu, T. (2025) · ResearchWorks at the University of Washington (University of Washington)
Gburek‐Augustat, J., Lee, I., Rubino, M., Topçu, V., Chavez-Castillo, M. F., Tu, S. C., Shinawi, M. S., Alfradique‐Dunham, I., Valtcheva, M. V., Adarmes‐Gómez, A., et al. (2026) · Epilepsia Open · doi:10.1002/epi4.70233 · Cited by 1
“…and cortical hyper-excitability; 19 LEV binds synaptic vesicle 2A (SV2A) to modulate neurotransmitter release and attenuate hyper-synchrony; 46 VPA augments GABAergic inhibition while blocking voltage-gated sodium/T-type calcium channels and curbing glutamate release to target…”
Genel, O., Alzarouni, S., Mirza, A. B., Ghimire, P., Murden, S., Chowdhury, Y. A., Elhag, A., Cikurel, K., Joe, D., Finnerty, G. T., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag035
Mačiulaitienė, R. (2025) · Lithuanian University of Health Sciences
Refractory hypokalemia associated with levetiracetam: a case report
Ksentini, M., Atheymen, R., Mahmoud, L. B., Ali, N. E. H. B., Hakim, A., Zghal, K., & Kammoun, B. (2026) · Pan African Medical Journal · doi:10.11604/pamj.2026.53.87.51338
“While levetiracetam has long been celebrated for its pharmacological neutrality, our clinical observation adds to a growing body of evidence suggesting that its metabolic impact may be more significant than previously recognized [6,7].”
tert ‐Butyl Nitrite‐Induced Cyclization Reactions in the Construction of Heterocyclic Compounds
Perumal, K., & Ramesh, S. (2026) · Chemistry - An Asian Journal · doi:10.1002/asia.70624
Alqahtani, M. Y., Alghamdi, A. S., Alghamdi, S. A., Binshaya, A. S., Safhi, A. Y., Sabei, F. Y., Abalkhail, A., & Alissa, M. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103564
Innovative electrochemical detection of major antiepileptic drugs
Nemati, S. S., Sadeghi, L., Marefat, A., & Dehghan, G. (2026) · Measurement Sensors · doi:10.1016/j.measen.2026.102004
Gapińska, N., Właź, P., Wyska, E., Świerczek, A., Kamiński, K., Jakubiec, M., Ciepiela, K., Abram, M., Latacz, G., Poleszak, E., et al. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111046
Hamid, G. A., Elmasry, G. F., El‐Moghazy, S. M., & Abd‐Allah, W. H. (2026) · Drug Development Research · doi:10.1002/ddr.70317
Effectiveness of Levetiracetam Versus Phenytoin in Acute Management of Childhood Seizures
Khalid, R., Iqbal, A., Waqar, T., Ghafoor, M., Awan, A. A., & Ejaz, H. (2026) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v76i3.12175
Dehpour, T., Vaezi, G., Juibari, A. D., Masoudian, N., & Hojati, V. (2026) · Current Issues in Pharmacy and Medical Sciences · doi:10.12923/cipms-2026-0011
LRRC57/RABIN is a presynaptic inhibitor of Rab GTPases in glutamatergic neuronsPreprint
Garić, D., Murphy, J. G., Teubner, B. J. W., Davenport, C. M., Shreffler, C. D., Janke, L. J., Cho, W. J., Wu, Z., McReynolds, M. G., Phasuk, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.05.743108
Shnayder, N. A., Владимировна, Г. В., Pekarets, N. I., Bykov, Y. N., Shirukova, A. M., & Nasyrova, R. F. (2026) · Epilepsy and Paroxysmal Conditions · doi:10.17749/2077-8333/epi.par.con.2026.274
van der Valk, J. C., Kalkers, N. F., & Blom, J. D. (2026) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2026.100348
Chen, Y., Shan, Q., Ma, P., Zhao, Y., Zhao, W., & Guo, J. (2026) · Intelligent Pharmacy · doi:10.1016/j.ipha.2026.08.009
Subbotin, A., Volk, H. A., Meller, S., Mazzuoli‐Weber, G., & Elfers, K. (2026) · Pharmaceuticals · doi:10.3390/ph19091356
“Although the predominant mechanism of action of levetiracetam is its high-affinity binding to SV2A [65], additional mechanisms have been described [66], including suppression of AMPA receptor-mediated currents [67], weak modulation of GABA A receptors [68], inhibition of N-and P/Q-type VGCCs…”
Zhao, W., Chen, Y., Zhao, Y., Shan, Q., Ma, P., & Guo, J. (2026) · Intelligent Pharmacy · doi:10.1016/j.ipha.2026.08.011
Levetiracetam in stroke: A narrative review of neuroprotective mechanisms and therapeutic potential
Hojjat, S. H., Rasouli, F., & Fathi‐karkan, S. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116454
Mindreanu, R., Clichici, S. V., Buleteanu, B., Badea, M., Pop, M., Cherecheș, R. M., & Login, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188410
“Rodent models of temporal lobe epilepsy describe modulation of mitochondrial dysfunction, inflammatory signalling and antioxidant enzyme activity [5,6], whereas LEV given to non-epileptic animals increased hippocampal DNA oxidation and oxidized glutathione [7].”
Rahman, I. U., Noureen, N., & Yousuf, M. (2025) · Pakistan Journal of Medical & Cardiological Review
Drug Repurposing in Cancer Therapy: A Review of Therapeutic Potential Across Diverse Drug Classes
Yadav, V., Mandaliya, V. B., & Shah, U. (2026) · ChemistrySelect · doi:10.1002/slct.202506782
Mondino, A., Nettifee, J. A., Simon, K. E., Papich, M. G., & Muñana, K. R. (2026) · American Journal of Veterinary Research · doi:10.2460/ajvr.26.08.0360
Islam, M. A., Akhter, S., Urmi, M. I., Osman, M., Aurpa, N. N., Akter, J., Amin, S. M. A., Ahmed, K. G. U., Mahmud, R., & Abdullah, M. A. A. (2026) · Cureus · doi:10.7759/cureus.118916
Kumar, B., Singh, K. K., Jerom, J. K., Singh, G., Kumar, S., Srivastava, Y. P., & Kirtania, J. (2026) · Indian Journal of Critical Care Case Report · doi:10.5005/jp-journals-11006-0247
Chen, X., Lin, X.-L., & Wen, Z. (2026) · Epileptic Disorders · doi:10.1002/epd2.70449
Metadata
- Authors
- Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A.
- Affiliations
- Laboratorio de Fisiología, Escuela Militar de Graduados de Sanidad, Ciudad de México 11200, Mexico
- Laboratorio de Neurociencias, Subdirección de Medicina Experimental, Instituto Nacional de Pediatría, Ciudad de México 04530, Mexico
- Laboratorio de Diseño Asistido por Computadora y Síntesis de Fármacos, Facultad de Química, Universidad Autónoma de Querétaro, Centro Universitario, Querétaro 76010, Mexico
- Secretaria de Salud (MX)
- Instituto Politécnico Nacional (MX)
- Laboratorio de Bioquímica Genética, Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de México 04530, Mexico
- Laboratorio de Inmunoquímica, Hospital Infantil de México Federico Gómez, Secretaría de Salud, Ciudad de México 06720, Mexico
- Departamento de Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2022-04-13
- Volume
- 15
- Issue
- 4
- Pages
- 475
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC9030752
- OpenAlex
- W4223993843
- Cited by
- 131
- References
- 303
- Citations by year
- 2026: 28 · 2025: 45 · 2024: 37 · 2023: 21
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- levetiracetam, antiepileptic drugs, epilepsy, seizure control, SV2A, calcium homeostasis, GABAergic system, AMPA receptors, multi-target drugs, drug repurposing, neuroprotection, anti-inflammatory activity, antioxidant activity, molecular targets
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.